SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 18792.
  • 2
    Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet 1970; 2: 114953.
  • 3
    McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up. Hepatology 1989; 9: 97101.
  • 4
    Trépo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970; 19: 4101.
    Direct Link:
  • 5
    Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome in a French urban population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51: 929.
  • 6
    Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, et al. A short course of prednisolone in chronic type B hepatitis: report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1986; 104: 127.
  • 7
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma [letter]. Blood 1996; 87: 1202.
  • 8
    Hess G, Manns M, Hutteroth TH, Meyer zum Buschenfelde KH. Discontinuation of immunosuppressive therapy in hepatitis B surface antigen-positive chronic hepatitis: effect on viral replication and on liver cell damage. Digestion 1987; 36: 4754.
  • 9
    Chemotherapy and hepatitis B [editorial]. Lancet 1989; 2: 11367.
  • 10
    Trépo C, Ouzan D, Delmont J, Tremisi J. [ Superiority of a new etiopathogenic treatment curing periarteritis nodosa caused by hepatitis B virus, using a combination of brief corticotherapy, vidarabine and plasma exchange]. In French. Presse Méd 1988; 17: 152731.
  • 11
    Guillevin L, Merrouche Y, Gayraud M, Jarrousse B, Royer I, Leon A, et al. Périartérite noueuse due au virus de l'hépatite B: détermination d'une nouvelle stratégie thérapeutique chez 13 patients. Presse Méd 1988; 17: 15226.
  • 12
    Guillevin L, Lhote F, Léon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges: a prospective trial in 33 patients. J Rheumatol 1993; 20: 28998.
  • 13
    Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 3347.
  • 14
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al, Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 15
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al, Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 618.
  • 16
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 125663.
  • 17
    Nakhoul F, Gelman R, Green J, Khankin E, Baruch Y. Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review. Transplant Proc 2001; 33: 29489.
  • 18
    Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-Avila JF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8: 892900.
  • 19
    Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002; 24: 3441.
  • 20
    Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33: 108893.
  • 21
    Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 1728.
  • 22
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 23
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315.
  • 24
    Prince AM, Trepo C. Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet 1971; 1: 130912.
  • 25
    Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74: 23853.
  • 26
    McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599603.
  • 27
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 28
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis Be antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 29
    Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60: 816.
  • 30
    Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001; 35: 40611.
  • 31
    Yang SS, Hsu CT, Hu JT, Lai YC, Wu CH. Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B. World J Gastroenterol 2002; 8: 86871.
  • 32
    Wicki J, Olivieri J, Pizzolato G, Sarasin F, Guillevin L, Dayer JM, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology 1999; 38: 1835.
  • 33
    Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol 2000; 33: 67783.
  • 34
    Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 3916.